Question 1

What is AnaCardio?

Accepted Answer

AnaCardio is a Entity.

Question 2

How often does AnaCardio appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 12 articles.

Question 3

When was AnaCardio first tracked by Ergen?

Accepted Answer

First tracked on Jun 24, 2026.

Question 4

When was AnaCardio last mentioned in news?

Accepted Answer

Last active on Jun 28, 2026.

Question 5

What is AnaCardio's current news sentiment?

Accepted Answer

Aggregate sentiment score: 75 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is AnaCardio in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving AnaCardio?

Accepted Answer

AnaCardio AC01 GOAL-HF1 Study Published (Jun 24, 2026, 12 articles).

Question 8

How did the "AnaCardio AC01 GOAL-HF1 Study Published" event impact AnaCardio?

Accepted Answer

AnaCardio announced the publication of positive Phase 1b/2a GOAL-HF1 study results for its drug AC01 in The Lancet, validating its potential as a treatment for heart failure with reduced ejection fraction (HFrEF) and supporting its advancement to Phase 2b clinical development. This is a significant milestone for the company.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.